Please login to the form below

Not currently logged in
Email:
Password:

abemaciclib

This page shows the latest abemaciclib news and features for those working in and with pharma, biotech and healthcare.

Lilly boosted by survival data for key growth drug Verzenio

Lilly boosted by survival data for key growth drug Verzenio

In the study, Verzenio (abemaciclib) – given alongside hormonal drug fulvestrant – was better than fulvestrant plus placebo at extending the lives of women with hormone receptor-positive, HER2-negative advanced breast cancer

Latest news

More from news
Approximately 7 fully matching, plus 25 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics